Please login to the form below

Not currently logged in
Email:
Password:

Frank Pieters leaves Teva to lead Cipla’s respiratory business

Will head up attempt to capitalise on the expiry of major pharma patents, such as that of GSK's Advair

Frank Pieters has left Teva Pharmaceutical to join India-based generics company Cipla as head of its European region and global respiratory business.

Pieters was most recently senior VP Southern Europe at Israel-based Teva – the largest generics company in the world.

His latest move signals an intent from Cipla to take advantage of the patent expiries for leading respiratory products, including GlaxoSmithKline's (GSK) Advair, which Cipla has a generic version.

“With [Pieters] at the helm, Cipla would like to capture the huge commercial upside of 30 years experience in Cipla's respiratory medicine; both in emerging and regulated markets,” said Dr Yusuf Hamied, chairman and managing director, Cipla.

“This appointment signals Cipla's strengthening of senior management positions and also illustrates Cipla's desire for senior on-ground talent in overseas markets to build its product portfolio and brand.”

During his time at Teva, Pieters also served as senior VP global biogenerics and global respiratory commercial business and he was also a member of the TEVA-Lonza Joint Steering Committee.

From 1989 to 2004, he held several senior positions at GSK, including VP and general manager.

6th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

Anthill_icon_Green_17_Multi-channel.png
Can you access your own content?
The rapid development of multichannel communication opens new opportunities to provide high-value experiences for healthcare professionals and gives you more places than ever to tell your product story. But unless...
How will capitated budgets affect NHS spending?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess the implications of a single budget covering all the physical, mental and social care needs of patients in an STP...
Dissecting adherence to personalise patient support
Across the healthcare and pharmaceutical industries, the initiatives to better understand the patient journey and lower healthcare costs have been growing in magnitude. One solution that has repeatedly been raised...

Infographics